ZERO WINTERDEAL 2025: Bis zu 300 € Prämie + Gratis-Aktie + finanzen.net MSCI World-ETF - Jetzt informieren!

This Drug Discovery Stock Is Leading the Charge In Bringing AI to Healthcare. But Is It a Buy?

16.10.25 10:31 Uhr

Werte in diesem Artikel

Veeva Systems (NYSE: VEEV) ticks a lot of the boxes that successful growth-seeking investors tend to look for. It boasts a dominant market position, it realizes recurring revenue from sticky subscription services, and it's exposed to the artificial intelligence (AI) megatrend that's reshaping healthcare.For over a decade, Veeva Systems has been building the connective tissue that drugmakers will need to integrate AI into their drug discovery pipelines. Unfortunately for new investors, Veeva's prescient positioning isn't a secret. The stock has been trading at a steep valuation.Let's take a closer look at the biopharmaceutical industry's favorite software vendor to see if its shares are a smart buy at recent prices.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Ausgewählte Hebelprodukte auf Ai

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Ai

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: MotleyFool

Nachrichten zu Ai Holdings Corp

Wer­bung